The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.
| Τίτλος | The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. |
| Publication Type | Journal Article |
| Year of Publication | 2014 |
| Authors | Lakis, S., Kotoula V., Eleftheraki A. G., Batistatou A., Bobos M., Koletsa T., Timotheadou E., Chrisafi S., Pentheroudakis G., Koutras A., Zagouri F., Linardou H., & Fountzilas G. |
| Journal | Breast |
| Volume | 23 |
| Issue | 3 |
| Pagination | 234-43 |
| Date Published | 2014 Jun |
| ISSN | 1532-3080 |
| Λέξεις κλειδιά | Androgen Receptor Antagonists, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Breast Neoplasms, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local, Prognosis, Receptors, Androgen, Receptors, Estrogen, Risk Assessment, Survival Analysis, Taxoids |
| Abstract | The Androgen Receptor (AR) is a potential prognostic marker and therapeutic target in breast cancer. We evaluated AR protein expression in high-risk breast cancer treated in the adjuvant setting. Tumors were subtyped into luminal (ER+/PgR±/AR±), molecular apocrine (MAC, [ER-/PgR-/AR+]) and hormone receptor negative carcinomas (HR-negative, [ER-/PgR-/AR-]). Subtyping was evaluated with respect to prognosis and to taxane therapy. High histologic grade (p < 0.001) and increased proliferation (p = 0.001) more often appeared in MAC and HR-negative than in luminal tumors. Patients with MAC had outcome comparable to the luminal group, while patients with HR-negative disease had increased risk for relapse and death. MAC outcome was favorable upon taxane-containing treatment; this remained significant upon multivariate analysis for overall survival (HR 0.31, 95%CI 0.13-0.74, interaction p = 0.035) and as a trend for time to relapse (p = 0.15). In conclusion, AR-related subtyping of breast cancer may be prognostic and serve for selecting optimal treatment combinations. |
| DOI | 10.1016/j.breast.2014.02.013 |
| Alternate Journal | Breast |
| PubMed ID | 24703723 |
